Spotlight On... Med tech entrepreneur Alfred Mann dies at age 90; NIH backs Cogito, Mass General in depression, bipolar study; Mindray shareholders vote to take private; and more...

The founder of insulin pump maker MiniMed, "bionic eye" company Second Sight Medical Products ($EYES) and inhaled insulin provider MannKind ($MNKD) has died at the age of 90. The cause of his death is not yet known. Alfred Mann founded 17 companies over his years, including some in the pharma and aerospace industries. He sold many of them, including MiniMed to Medtronic ($MDT) for $3.3 billion in 2011, and was worth more than $2 billion in 2007. His latest venture turned out to one of his few misses. Although Mann spent almost $1 billion of his own money to secure FDA approval of inhaled insulin med Afrezza, the combination product appears to be a flop (as many predicted), and former marketing partner Sanofi stopped supporting the therapy after a handful of months. Second Sight IPO'd in November 2014. Although its stock has fallen since the company's debut on the Nasdaq, it last year released promising data on its Argus II Retinal Prosthesis System for patients who are blind due to due to retinitis pigmentosa. More   

@FierceMedDev: ICYMI: Boston Scientific's Brazilian operations under investigation, as co-founder to depart. Story | Follow @FierceMedDev

@EmilyWFierce: Intel hops on the precision medicine bandwagon with new projects for 2016. News | Follow @EmilyWFierce

> Behavioral analytics company Cogito has partnered with Boston's Massachusetts General Hospital's MoodNetwork to better understand depression and bipolar disorder; the initiative is funded by a $1.8 million grant from the National Institute of Mental Health. More

> Mindray ($MR) have voted to accept the previously announced take-private proposal. More

> The University of California at San Francisco and healthcare tech company CipherHealth have partnered to create a care management platform named View to improve the quality of care for patients with complex medical conditions. More

Biotech News

@FierceBiotech: Charities and pharma decry 'disgraceful' changes to England's Cancer Drugs Fund. Story | Follow @FierceBiotech

@JohnCFierce: Glad to see the top trending story yesterday was the Exicure profile. Doesn't always happen with little biotechs. Story | Follow @JohnCFierce

@DamianFierce: Wired is getting into dystopian fiction. Wired story | Follow @DamianFierce

> FierceBiotech Radio on the FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation.' Listen

> Report: Fatal French trial ignored preclinical warning signs. News

> Lilly rolls toward EU approval with a potential psoriasis blockbuster. More

Pharma News

@FiercePharma: Look out, drugmakers: NICE is taking the reins of England's Cancer Drugs Fund. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Short on label expansions, Pfizer nabs FDA OK for new, once-daily Xeljanz. Story | Follow @CarlyHFierce

> Opdivo wins thumbs up from CHMP for two indications, in lung and kidney cancers. News

> Analyst: Valeant better bring back Pearson if it wants to stay in the game. More